Navigation Links
Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
Date:10/27/2008

the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The company expects that the first microRNA diagnostic tests applying its technology will be launched by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the expected timing or the repurchase of the remaining ARS by Credit Suisse, the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the expected timing of submission for approval and launch of diagnostic tests using our microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
2. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
3. AviaraDx Announces CAP Accreditation of Its Laboratory Operations
4. Angiotech to participate in Bank of America 2007 Credit Conference
5. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
6. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
7. Credit-card-sized platform for volatile compound analysis CAREER project goal
8. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
9. GeneNews receives ISO 13485 accreditation
10. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
11. Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... New York (PRWEB) August 22, 2014 ... one of the interesting and challenging endeavors as ... renders highly impervious properties to the foreign substances. ... as possibility of self medication and minimal use ... low molecular weight drugs and provides specific targeting ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, ... report to their offering. The global ... in 2013, and is expected to grow at a ... Molecular biology enzymes, kits, & reagents find applications in ...
(Date:8/22/2014)... Canada (PRWEB) August 22, 2014 ... in model organisms can be accelerated by exome ... and manufacturing technologies, the custom SeqCap EZ Developer ... research. , Mr. Watson will additionally present how ... with commercially available human and mouse exome kits. ...
(Date:8/21/2014)... MD (PRWEB) August 21, 2014 DNA ... making progress in its development of JRC-LAMP-vax, an innovative ... cedar pollen. Phase IC studies began this month in ... to hay fever. , The Japanese red cedar releases ... people in Japan. Mountain Cedar pollen wreaks similar havoc ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4
... and GAITHERSBURG, Maryland, November 2, 2011 ... -based HPV Testing Increases Screening Coverage and is More ... Online in the Lancet Promising findings published ... a community-based, randomized equivalence trial undertaken by public health authorities ...
... announced that data from REMEDEE ( R andomized ... sirolimus coat ED bio- E ngineered ... Combo Bio-engineered Sirolimus Eluting Stent (Combo Dual Therapy Stent), will be ... Session at TCT 2011 in San Francisco. The presentation entitled "REMEDEE: ...
... Pharmaceuticals, Inc. (NASDAQ: OPTR ) today announced ... Credit Suisse Healthcare Conference on Thursday, November 10 at ... (Logo:   http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) A live ... the Investors page of the Company,s website at ...
Cached Biology Technology:Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 2Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 3Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 4Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 5Data From REMEDEE Trial Featuring OrbusNeich's Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011 2Data From REMEDEE Trial Featuring OrbusNeich's Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011 3
(Date:8/21/2014)... Conn. , Aug. 21, 2014 Nxt-ID, ... the growing mobile commerce market, announced today that its ... common stock to be issued in its proposed underwritten ... approved for listing on The Nasdaq Capital Market, subject ... the common stock and warrants, and will trade under ...
(Date:8/21/2014)... study aimed at improving the food intake, health and ... homes is among three projects at the University of ... the Canadian Institutes of Health Research (CIHR). , ... Sciences at Waterloo, and a Schlegel research chair in ... to investigate why many Canadians living in long-term care ...
(Date:8/21/2014)... , Saturday to Wednesday, Oct. 18-22, 2014 , ... W. Harbor Drive, San Diego, CA 92101 , ... and other presentations of the latest research in ... plenary session featuring high-scoring abstracts on rare genetic ... various cancers, and treatment for sun sensitivity (Saturday, ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... is available in Spanish . , The ... other forms of synaesthesia in which flavours are evoked ... time units, colours by music, etc. Experts on Experimental ... phenomenon. The results of this research have been published ...
... the ravages the disease can take on almost every ... addictive behaviors, even after a period of peaceable abstinence" ... brain active during decision making. "It,s perhaps ... that they have trouble thinking through a decision," said ...
... skates (skates made of animal bones) are the oldest ... BC. Why people started skating on ice and where ... in several locations spread across Central and North Europe. ... Journal of the Linnean Society of London, Dr Formenti ...
Cached Biology News:1 person out of every 1,000 has synaesthesia, in which an individual can smell a sound 21 person out of every 1,000 has synaesthesia, in which an individual can smell a sound 31 person out of every 1,000 has synaesthesia, in which an individual can smell a sound 4Cognitive, genetic clues identified in imaging study of alcohol addiction 2Cognitive, genetic clues identified in imaging study of alcohol addiction 3Cognitive, genetic clues identified in imaging study of alcohol addiction 4
...
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... Recombinant Ribonuclease Inhibitor is a ... ribonucleases such as RNase A. ... Recombinant Ribonuclease Inhibitor is an ... weight ~52 kDa. RNaseOUT inhibits ...
... Inhibitor (Ribonuclease inhibitor) is a ... to inhibit RNase activity. It ... endonuclease activity. , Inhibits ... RNA template , Lacks ...
Biology Products: